Purchasing
Purchasing at Boehringer Ingelheim
Search
Boehringer Ingelheim’s latest investigational treatment slowed lung function decline in people living with idiopathic pulmonary fibrosis
Promising 12-week Phase II trial data with BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor, published in The New England Journal of Medicine Potential new treatment for progressive pulmonary fibrosis (PPF) builds on Boehringer
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Accelerating innovation in health : Boehringer Ingelheim and the Vector Institute to collaborate on AI
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
Boehringer Ingelheim Focuses COVID-19 Clinical Research on Alteplase
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
New partnership in Alberta supports healthcare solutions for interstitial lung diseases
First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Boehringer Ingelheim Canada supports PF Awareness Month with Life with PF campaign
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
Boehringer Ingelheim (Canada) Ltd. partners with LMC Healthcare on national diabetes prevention program
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Boehringer Ingelheim’s survodutide shows significant improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
University Health Network and Boehringer Ingelheim Canada partner to impact patients lives and help a healthcare system under strain
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
Research Manitoba, Boehringer Ingelheim Canada and First Nations Health and Social Secretariat of Manitoba Announce Chronic Kidney Disease Screening Program in the Manitoba Adult First Nations Population
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
New collaboration between Boehringer Ingelheim and Sleip leverages AI technology to help detect lameness in horses
Business Ethics
The ethical principles that have guided Boehringer Ingelheim for 130 years created a culture of corporate and social responsibility and commitment.
Corporate profile
Corporate profile
World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program
World’s first horse inhaler for equine asthma “saddles up” with terracycle for recycling program
Treatment options for parasite control in cattle
Treatment options for parasite control in cattle
R&D - Transforming tomorrow
Manami Tsutsumi, Senior Associate Director in Research & Development describes what it's like working on the cutting edge of pharmaceutical development.
Effective management practices for parasite control in cattle
Effective management practices for parasite control in cattle
Alberta
Learn about Boehringer Ingelheim Canada's strategic partnerships with leading institutions in Alberta to advance quality healthcare.
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
Innovative project launched using advanced digital technology to transform management of complex care for patients with heart failure
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
OFEV® (nintedanib) receives positive recommendation from CADTH and INESSS for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD)
Ontario
Boehringer Ingelheim Canada collaborates with premier institutions in Ontario to drive innovative solutions for high-quality healthcare. Click to read more.
Strategies for overcoming resistance in parasites
Strategies for overcoming resistance in parasites
Western Canada
Boehringer Ingelheim Canada works hand in hand with prominent institutions in Western Canada. Find out more about our partnerships and their initiatives.
Quebec
Boehringer Ingelheim Canada joins forces with top institutions in Quebec to foster excellence in healthcare. Find out more about our partnering activities.